At Holdings Channel, we have reviewed the latest batch of the 26 most recent 13F filings for the 12/31/2025 reporting period, and noticed that Vertiv Holdings Co (Symbol: VRT) was held by 11 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look. Before we proceed, it is important to point out that 13F filings do not tell the whole sto...
At Holdings Channel, we have reviewed the latest batch of the 26 most recent 13F filings for the 12/31/2025 reporting period, and noticed that Vertiv Holdings Co (Symbol: VRT) was held by 11 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look. Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen. Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in VRT positions, for this latest batch of 13F filers: In terms of shares owned, we count 3 of the above funds having increased existing VRT positions from 09/30/2025 to 12/31/2025, with 4 having decreased their positions and 1 new position. Looking beyond these particular funds in this one batch of most recent filers, we tallied up the VRT share count in the aggregate among all of the funds which held VRT at the 12/31/2025 reporting period (out of the 4,456 we looked at in total). We then compared that number to the sum total of VRT shares those same funds held back at the 09/30/2025 period, to see how the aggregate share count held by hedge funds has moved for VRT. We found that between these two periods, funds reduced their holdings by 2,477,503 shares in the aggregate, from 81,231,543 down to 78,754,040 for a share count decline of approximately -3.05%. The overall top three funds hold...
Getty Images Super Micro Computer, Inc. ( SMCI ) reported earnings last week in what has been a tough few months for the stock. After climbing near the $60 range twice since the tariff wars of April 2025, SMCI has fallen off hard and now languishes in the mid-$30s as investors weigh the company's future prospects. I continue to be bearish, and I see growing revenues as a red herring, distracting f...
Getty Images Super Micro Computer, Inc. ( SMCI ) reported earnings last week in what has been a tough few months for the stock. After climbing near the $60 range twice since the tariff wars of April 2025, SMCI has fallen off hard and now languishes in the mid-$30s as investors weigh the company's future prospects. I continue to be bearish, and I see growing revenues as a red herring, distracting from persistent margin erosion. Data by YCharts In my last piece on SMCI, I discussed the company's preliminary Q1 2026 results and how, despite upbeat revenue projections for FY2026, the inability to improve margins makes it hard to recommend the stock. I reiterated a Sell, and shares have since fallen 30% relative to a 3% gain for the S&P 500 ( SPY ). That article can be read here . Going back even further, I first covered SMCI back in September 2024 with an article subtitled "This Stock Is Dead Money," and the comments were full of folks hoping against hope that the company could turn it around. SMCI is down 20% since then relative to a 20% gain for the SPY. So it is, we now find ourselves yet again at a hopeful moment in time for SMCI shareholders on the heels of a bullish earnings report as investor sentiment seems poised for a reversal. Will this time be different? Let's start with a quick recap of the Q2 2026 earnings report: Super Micro Q2 2026 Earnings Presentation Super Micro stated last quarter, when it missed revenue by a fair bit, that much of the gap would be realized in Q2 due to an order postponement by a major customer, and it appears that is the case here. Revenue ballooned to $12.7 billion, up substantially YoY and QoQ, as increasing expenditures for AI data centers rippled through the industry. On the downside, gross margin declined YoY and QoQ, and EPS only grew by 16% YoY despite the explosion in revenue. This has been Super Micro's problem for a few quarters now and is, in my opinion, the crux of the bear thesis -- the company continues to earn more re...
Earnings Call Insights: Cincinnati Financial Corporation (CINF) Q4 2025 Management View President and CEO Stephen Spray stated the company "had another excellent quarter of operating performance that again demonstrated the resilience of our proven operating model and the long-term strategy that drives our insurance business." Net income for full year 2025 reached $2.4 billion, up 4% from 2024, whi...
Earnings Call Insights: Cincinnati Financial Corporation (CINF) Q4 2025 Management View President and CEO Stephen Spray stated the company "had another excellent quarter of operating performance that again demonstrated the resilience of our proven operating model and the long-term strategy that drives our insurance business." Net income for full year 2025 reached $2.4 billion, up 4% from 2024, while fourth quarter net income was $676 million, a 67% increase. Spray highlighted that "non-GAAP operating income for the quarter increased 7% to $531 million" and the property casualty combined ratio for Q4 was 85.2%, lowering the full year combined ratio to 94.9%. He indicated the company's pricing discipline led to a slowdown in net written premium growth to 5% for the quarter, with "estimated average renewal price increases for most lines of business during the fourth quarter... lower than the third quarter of 2025, but still at a level we believe was healthy." Spray discussed adjustments in reinsurance, noting, "The treaty's main change this year is increasing the top of the program to $2 billion compared with $1.8 billion, effective July 1, 2025." He projected 2026 ceded premiums for these treaties to be approximately $204 million, up from $192 million in 2025. The CEO also emphasized ongoing investments in intelligent automation and generative AI, sharing, "We have a number of projects completed, and even more on the road map," including a proprietary chatbot for underwriters. CFO Michael J. Sewell stated, "Investment income was a significant contributor to higher net income and improved operating results, rising 9% for the fourth quarter and 14% for the full year 2025 compared with the same periods of last year." He reported net purchases of fixed maturity securities totaled $1.6 billion for 2025, and cash flow from operating activities for the year was $3.1 billion, up 17%. Outlook Spray explained, "We are confident that our rates, our pricing are exceeding loss cos...
Blackstone Inc. is preparing to debut a slew of products for its wealth and retirement strategies as it readies its existing offerings for inclusion in target-date funds, Chief Financial Officer Michael Chae said. The firm filed registration statements for two products it plans to launch later this year as part of its partnership with Wellington Management Co. and Vanguard Group , he said at a fin...
Blackstone Inc. is preparing to debut a slew of products for its wealth and retirement strategies as it readies its existing offerings for inclusion in target-date funds, Chief Financial Officer Michael Chae said. The firm filed registration statements for two products it plans to launch later this year as part of its partnership with Wellington Management Co. and Vanguard Group , he said at a financial conference Tuesday. Blackstone is also seeking to debut a new perpetual multiasset fund for its wealth strategy. Blackstone manages more than $160 billion across its four strategies for individual investors, he said. “These strategies are really foundational for our next phase of growth — particularly around multiasset products and the retirement channel — which represents really a whole new dimension of our wealth business,” Chae said. Alternative asset managers are vying for a slice of the roughly $12 trillion sitting in Americans’ 401(k)s and other defined-contribution retirement plans, spurred in part by a White House order aimed at making it easier to include private assets in such funds. Blackstone and competitors such as Carlyle Inc. and Apollo Global Management Inc. have been building out teams and rolling out new partnerships and products to grab a share of the retirement and wealth market. “We’re still in the very early stages of investor adoption in what is a $140 trillion global market,” Chae said, referring to the wealth held by individuals around the world. In August, President Donald Trump directed the US Department of Labor to reevaluate guidance around the inclusion of alternative assets in 401(k) accounts. Retirement plan administrators have historically been loath to include relatively illiquid, riskier private assets in defined-contribution plans because of concerns over being sued for allegedly breaching their fiduciary duties. Private-asset investment firms are awaiting a final rule from the department, which could ease such fears. “In the meant...
The National Cancer Institute is using federal funds to study whether cancer can be cured by ivermectin, a cheap, off-patent anti-parasitic and deworming drug that fringe medical groups falsely claimed could treat COVID-19 during the pandemic and have since touted as a cure-all. Large, high-quality clinical trials have resoundingly concluded that ivermectin is not effective against COVID-19 . And ...
The National Cancer Institute is using federal funds to study whether cancer can be cured by ivermectin, a cheap, off-patent anti-parasitic and deworming drug that fringe medical groups falsely claimed could treat COVID-19 during the pandemic and have since touted as a cure-all. Large, high-quality clinical trials have resoundingly concluded that ivermectin is not effective against COVID-19 . And there is no old or new scientific evidence to support a hypothesis that ivermectin can cure cancer—or justify any such federal expenditure. But, under anti-vaccine Health Secretary Robert F. Kennedy Jr.—who is otherwise well-known for claiming to have a parasitic worm in his brain—numerous members of the medical fringe are now in powerful federal positions or otherwise hold sway with the administration. During a January 30 event, Anthony Letai, a cancer researcher the Trump administration installed as the director of the NCI in September, said the NCI was pursuing ivermectin. Read full article Comments
Vuk Saric/E+ via Getty Images The last few months have been rather painful for shareholders of toy and costume company JAKKS Pacific, Inc. ( JAKK ). Back in October of last year, I acknowledged that the business was experiencing pain. But I viewed that pain as temporary. I found myself encouraged by some of the progress management was making. And that ultimately led me to call it a "Buy," even tho...
Vuk Saric/E+ via Getty Images The last few months have been rather painful for shareholders of toy and costume company JAKKS Pacific, Inc. ( JAKK ). Back in October of last year, I acknowledged that the business was experiencing pain. But I viewed that pain as temporary. I found myself encouraged by some of the progress management was making. And that ultimately led me to call it a "Buy," even though the stock had already surged 74.2% in the time that I had been bullish on it leading up to that point . That compared to the 40.2% jump that the S&P 500 saw over the same window of time. Since then, however, weak financial performance achieved during the third quarter of the 2025 fiscal year pushed shares down 6.8%. The market, meanwhile, is up 2.7% in that time. As disappointing as this is, I remain confident in the company. So much so, in fact, that even with revenue plunging, I believe that maintaining it as a "Buy" candidate makes sense here. Of course, we should evaluate the picture as new data comes in. It just so happens that, later this month, management will be announcing financial results for the final quarter of the company's 2025 fiscal year. As of this writing, a specific date has not been announced. Last year, it was on Feb. 20. Leading up to that point, analysts expect revenue, profits, and adjusted profits to all contract year over year. But unless something big and unexpected negatively affects the enterprise, I believe that sticking to a bullish assessment is appropriate. Times Are Tough Author - SEC EDGAR Data The only new data that investors have right now for JAKKS Pacific covers through the third quarter of the company's 2025 fiscal year. During that quarter, revenue amounted to $211.2 million. This marks a massive drop from the $321.6 million the company reported a year earlier. With that decline in revenue came a drop in profits as well. Net income contracted from $52.3 million to $19.9 million. On an adjusted basis, the decline was from $54 mill...
Wealth management and tax planning companies fell on Tuesday after privately held financial software provider Altruist Corp. launched an AI tool that creates tax strategies for clients, generating concerns for other companies. Among the top decliners were LPL Financial Holdings ( LPLA ) -9.6%, The Charles Schwab Corp. ( SCHW ) -8.7%, Raymond James Financial ( RJF ) -8.6%, Stifel Financial ( SF ) -...
Wealth management and tax planning companies fell on Tuesday after privately held financial software provider Altruist Corp. launched an AI tool that creates tax strategies for clients, generating concerns for other companies. Among the top decliners were LPL Financial Holdings ( LPLA ) -9.6%, The Charles Schwab Corp. ( SCHW ) -8.7%, Raymond James Financial ( RJF ) -8.6%, Stifel Financial ( SF ) -4.9%, and Piper Sandler Companies ( PIPR ) -4.1%. “The selloff appears tied to broader concerns about AI disrupting the financial advice and wealth management model,” said Bloomberg Intelligence analyst Neil Sipes. These declines are “likely centering on concerns around efficiencies being competed away, fee compression long-term, and potential market share shifts,” he added. Here are the rest of the industry stocks and their Tuesday performance so far: LPL Financial Holdings Inc. ( LPLA ) - Day performance: -9.57%, SA Quant rating: 3.02 The Charles Schwab Corporation ( SCHW ) - Day performance: -8.68%, SA Quant rating: 3.42 Raymond James Financial, Inc. ( RJF ) - Day performance: -8.64%, SA Quant rating: 2.94 Stifel Financial Corp. ( SF ) - Day performance: -4.94%, SA Quant rating: 2.84 Piper Sandler Companies ( PIPR ) - Day performance: -4.12%, SA Quant rating: 2.99 BGC Group, Inc. ( BGC ) - Day performance: -3.77%, SA Quant rating: 2.30 Morgan Stanley ( MS ) - Day performance: -3.47%, SA Quant rating: 3.43 Perella Weinberg Partners ( PWP ) - Day performance: -2.63%, SA Quant rating: 2.28 Interactive Brokers Group, Inc. ( IBKR ) - Day performance: -1.72%, SA Quant rating: 4.39 Jefferies Financial Group Inc. ( JEF ) - Day performance: -1.13%, SA Quant rating: 2.32 Robinhood Markets, Inc. ( HOOD ) - Day performance: -1.01%, SA Quant rating: 3.09 StoneX Group Inc. ( SNEX ) - Day performance: -0.72%, SA Quant rating: 4.94 Virtu Financial, Inc. ( VIRT ) - Day performance: -0.66%, SA Quant rating: 3.07 PJT Partners Inc. ( PJT ) - Day performance: -0.65%, SA Quant rating: 2.94 Ho...
is a senior reporter who’s been covering and reviewing the latest gadgets and tech since 2006, but has loved all things electronic since he was a kid. Posts from this author will be added to your daily email digest and your homepage feed. The earliest backers of Sharge’s latest Kickstarter crowdfunding campaign can preorder the power bank for $149, while its full price is expected to be closer to ...
is a senior reporter who’s been covering and reviewing the latest gadgets and tech since 2006, but has loved all things electronic since he was a kid. Posts from this author will be added to your daily email digest and your homepage feed. The earliest backers of Sharge’s latest Kickstarter crowdfunding campaign can preorder the power bank for $149, while its full price is expected to be closer to $199 once delivery starts as early as May 2026. Inside the Shargeek 300 is a 24,000 mAh battery that can be fully recharged in 75 minutes using a 140W charger. The power bank is roughly the size of a soda can, but a bit taller at 6.25 inches long. Image: Sharge As the name implies, the Shargeek 300’s total output is 300W which is shared across two USB-C ports, a USB-A port, and a barrel-style DC port. Both USB-C ports can output up to 140W letting you simultaneously charge two power-hungry laptops while a third device pulls 20W from the USB-A port. The output of the DC port can be adjusted from as little as 25W up to 140W. The Shargeek 300 features a lightweight aluminum alloy frame wrapped in an aluminum shell that helps to dissipate heat. There’s also two cutaway sections, protected by transparent plastic windows, revealing some of the power bank’s electronics and a 1.9-inch screen on one side, and the batteries on the other. You can use the screen to monitor the battery’s charge level, power output, temperature, and adjust the DC output voltage. The exposed interior is also illuminated with RGB LEDs whose color, brightness, and function can be customized using the display.
Authorities investigating the disappearance of Nancy Guthrie released the first surveillance images on Tuesday showing a masked person on her porch the night she went missing, as law enforcement and her family intensified calls for public help more than a week into the search. Law enforcement searching for the mother of “Today” show host Savannah Guthrie has not identified any suspects or persons ...
Authorities investigating the disappearance of Nancy Guthrie released the first surveillance images on Tuesday showing a masked person on her porch the night she went missing, as law enforcement and her family intensified calls for public help more than a week into the search. Law enforcement searching for the mother of “Today” show host Savannah Guthrie has not identified any suspects or persons of interest, and it is unclear if she is still alive. FBI Director Kash Patel posted the images on social media. Advertisement “The video was recovered from residual data located in back end systems,” Patel wrote, saying the images show “an armed individual appearing to have tampered with the camera at Nancy Guthrie’s front door the morning of her disappearance”. Video released by the FBI shows the person wearing a backpack, long sleeves and pants walk up to the door and try to conceal a camera with a glove before turning around, grabbing some plants and then putting them in front of the camera. The FBI is seeking information on the identity of this individual seen at Nancy Guthrie’s front door. Photo: FBI via TNS Investigators had been hopeful that cameras at the home would turn up some evidence about how she went missing, but the doorbell camera was disconnected early on Sunday.
Micron’s stock has dropped on competitive concerns, but a Deutsche Bank analyst thinks the company can benefit from a memory boom that’s “still not well understood” by many investors.
Micron’s stock has dropped on competitive concerns, but a Deutsche Bank analyst thinks the company can benefit from a memory boom that’s “still not well understood” by many investors.
Malinowski concedes to Mejia in Democratic House special primary in New Jersey toggle caption Alex Wong/Getty Images Former congressman Tom Malinowski conceded Tuesday to challenger Analilia Mejia in the closely watched Democratic special election U.S. House primary to fill New Jersey Gov. Mikie Sherrill's vacated congressional seat. "I congratulate Analilia Mejia on her hard won victory in the NJ...
Malinowski concedes to Mejia in Democratic House special primary in New Jersey toggle caption Alex Wong/Getty Images Former congressman Tom Malinowski conceded Tuesday to challenger Analilia Mejia in the closely watched Democratic special election U.S. House primary to fill New Jersey Gov. Mikie Sherrill's vacated congressional seat. "I congratulate Analilia Mejia on her hard won victory in the NJ-11 special primary. I look forward to supporting her in the April general election," Malinowski said in a statement. The Associated Press has not yet made a call in the race. Last Thursday, Mejia led by a narrow margin as polls closed in the district. Some mail-in ballots remain to be counted. The Democratic nominee will face Randolph Township Mayor Joe Hathaway, the only Republican to run, in April's special general election to replace now-Gov. Mikie Sherrill. Sherrill resigned from her seat shortly after winning the gubernatorial race last November. Sponsor Message The special primary contest is one of the first elections in the 2026 midterm cycle where Democrats hope to capitalize on voter dissatisfaction with President Trump's second-term agenda. After losing the White House and the Senate in 2024, the party earned numerous victories in special elections and saw a surge of support in the 2025 November general election, including Sherrill's landslide victory. Malinowski's comeback bid was supported by New Jersey Sen. Andy Kim, who touted the two-term congressman's experience. "Tom Malinowski knows the House of Representatives. He knows Congress. He knows New Jersey," Kim said in a video. "He knows how to be able to stand up to Donald Trump, and that's what I need right now is someone there as a partner with me in the Capitol." Malinowski represented a neighboring congressional seat from 2018-2022, but lost to Republican Rep. Tom Kean Jr. after redistricting added more Republicans into his district. Malinowski's prior experience in Congress was an important factor in the...
ISerg/iStock via Getty Images The last time I spoke about Krystal Biotech ( KRYS ), it was with respect to a Seeking Alpha article entitled " Krystal Biotech: A Strong Buy Despite KB707 Melanoma Tumor Targeting Update ." With respect to this article, I noted that the company had put a pause on work on advancing its phase 1/2 OPAL study, which was using KB707 for the treatment of patients with adva...
ISerg/iStock via Getty Images The last time I spoke about Krystal Biotech ( KRYS ), it was with respect to a Seeking Alpha article entitled " Krystal Biotech: A Strong Buy Despite KB707 Melanoma Tumor Targeting Update ." With respect to this article, I noted that the company had put a pause on work on advancing its phase 1/2 OPAL study, which was using KB707 for the treatment of patients with advanced melanoma. The company has since shifted its focus towards developing inhaled gene therapy KB707 for the treatment of patients with advanced [2nd-line] non-small cell lung cancer [NSCLC]. Today I'm going to go over this program again, but I also want to highlight that there was a major update since I last spoke about this company. Just the other day the FDA granted KB707 as an inhaled gene therapy Regenerative Medicine Advanced Therapy [RMAT] designation for the treatment of these patients with advanced or metastatic NSCLC. The reason why this designation was given was on the basis of clinical data from the phase 1/2 KYANITE-1 study, which evaluated the use of this inhaled IL-12/IL-2 cytokine therapy to treat these patients. More about the latest RMAT designation below, but just know that the company obtains the benefits of both FDA Fast Track Designation [FTD] and Breakthrough Therapy Designation [BTD]. Besides this, another update is that the company spoke with the FDA in an end-of-phase 2 [EOP2] meeting, and the outcome was highly positive. The reason why is because it was noted that a single registrational trial using inhaled KB707 in combination with chemotherapy versus chemotherapy alone to treat patients with advanced NSCLC would be enough to allow for a regulatory filing. The company is expected to provide an interim analysis in the 2nd half of 2026 from the registrational cohort added to the phase 1/2 KYANITE-1 study. In addition, that is when it is expected to also provide an update on its registrational plans. As far as VYJUVEK goes in terms of sales, it is g...